---
title: "Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Indication questions"
description: "Indication questions on Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Gardasil 9 approved for? What ages is Gardasil 9 approved for? Is Gardasil 9 approved to prevent oropharyngeal and other head and neck cancers? Does Gardasil 9 replace cervical or anal cancer screening? 5 further questions follow. 9 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Indication questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Gardasil 9](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf)

Indication questions that apply to every indication of Gardasil 9 are on [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), all indications: Indication](https://www.evicenter.com/medical-information/gardasil-9/indication).

## Indication

<a id="gardasil9-indication"></a>

### What is Gardasil 9 approved for?

> “GARDASIL<sup>®</sup>9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=%28Human%20Papillomavirus%209%2Dvalent%20Vaccine%2C%20Recombinant%29%20is,HPV%20Types%206%20and%2011.)

> “GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=GARDASIL%209%20is%20indicated%20in,HPV%20Types%206%20and%2011.)

> “The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=The%20oropharyngeal%20and%20head%20and,benefit%20in%20a%20confirmatory%20trial.)

<a id="gardasil9-age-range"></a>

### What ages is Gardasil 9 approved for?

> “GARDASIL<sup>®</sup>9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is a vaccine for patients 9 through 45 years of age for the prevention of certain cancers and other diseases caused by 9 types of human papillomavirus (HPV).”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=%28Human%20Papillomavirus%209%2Dvalent%20Vaccine%2C%20Recombinant%29%20is%20a%20vaccine%20for,types%20of%20human%20papillomavirus%20%28HPV%29.)

<a id="gardasil9-head-and-neck-cancer"></a>

### Is Gardasil 9 approved to prevent oropharyngeal and other head and neck cancers?

> “The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=The%20oropharyngeal%20and%20head%20and,benefit%20in%20a%20confirmatory%20trial.)

> “Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=Not%20all%20vulvar%2C%20vaginal%2C%20anal%2C,33%2C%2045%2C%2052%2C%20and%2058.)

> “The effectiveness of GARDASIL 9 against oropharyngeal and other head and neck cancers caused by
> HPV types 16, 18, 31, 33, 45, 52 and 58, is based on the effectiveness of GARDASIL and GARDASIL 9
> to prevent anogenital disease caused by HPV types covered by the vaccine [see Clinical Studies (14.1,
> 14.2, 14.3)].”

Source: [GARDASIL 9: Prescribing information, page 18, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=18)

<a id="gardasil9-screening"></a>

### Does Gardasil 9 replace cervical or anal cancer screening?

> “GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=GARDASIL%209%20does%20not%20eliminate,by%20a%20health%20care%20provider.)

> “Vaccination does not eliminate the necessity for women to continue to undergo recommended
> cervical cancer screening. Women who receive GARDASIL 9 should continue to undergo cervical
> cancer screening per standard of care.”

Source: [GARDASIL 9: Prescribing information, page 26, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=26)

> “Recipients of GARDASIL 9 should not discontinue anal cancer screening if it has been
> recommended by a health care provider.”

Source: [GARDASIL 9: Prescribing information, page 26, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=26)

<a id="gardasil9-prior-hpv-exposure"></a>

### Does Gardasil 9 protect against HPV types a person was already exposed to?

> “GARDASIL 9 has not been demonstrated to provide protection against diseases caused by:
>
> HPV types not covered by the vaccine
> HPV types to which a person has previously been exposed through sexual activity”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=GARDASIL%209%20has%20not%20been,been%20exposed%20through%20sexual%20activity)

<a id="gardasil9-protection-not-universal"></a>

### Does Gardasil 9 protect everyone who is vaccinated?

> “Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=Vaccination%20with%20GARDASIL%209%20may,protection%20in%20all%20vaccine%20recipients.)

<a id="gardasil9-not-a-treatment"></a>

### Can Gardasil 9 treat genital warts, precancerous lesions, or HPV-related cancer?

> “GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; or cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), or anal intraepithelial neoplasia (AIN).”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=GARDASIL%209%20is%20not%20a,or%20anal%20intraepithelial%20neoplasia%20%28AIN%29.)

<a id="gardasil9-hpv-cancer-burden"></a>

### Gardasil 9 HPV types: US cancer cases per year (CDC, 2012-2016)?

Applies to: HPV-attributable cancer in the United States (CDC data cited by the manufacturer)

> “CDC-estimated 2012-2016 US incidence model of cancer cases attributed to 7 HPV types (16, 18, 31, 33, 45, 52, and 58)<sup>7</sup>”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) For Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-a/#:~:text=CDC%2Destimated%202012%2D2016%20US%20incidence%20model,31%2C%2033%2C%2045%2C%2052%2C%20and)

> “~31,400 HPV-attributable cancer cases per year<sup>7</sup>”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) For Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-a/#:~:text=~31%2C400%20HPV%2Dattributable%20cancer%20cases%20per)

> “The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) For Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-a/#:~:text=The%20oropharyngeal%20and%20head%20and,benefit%20in%20a%20confirmatory%20trial.)

> “US Cancer Statistics assessed incidence of HPV-associated cancers to estimate the annual number of cancers caused by HPV, overall, and by state in 2012-2016.<sup>7</sup>
>
> The estimated number of cancers attributable to HPV was calculated by multiplying the average number of HPV-associated cancers by the percentage of cancers diagnosed from 1993-2005 (prevaccine) that were attributable to HPV.<sup>7,10</sup>”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) For Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-a/#:~:text=US%20Cancer%20Statistics%20assessed%20incidence,%28prevaccine%29%20that%20were%20attributable%20to)

> “Not all cervical, vulvar, vaginal, anal, and oropharyngeal cancers are caused by HPV.<sup>7</sup>”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) For Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-a/#:~:text=Not%20all%20cervical%2C%20vulvar%2C%20vaginal%2C%20anal%2C%20and%20oropharyngeal%20cancers%20are%20caused%20by)

<a id="gardasil9-oropharyngeal-cancer-men"></a>

### Gardasil 9 background: most common HPV-related cancer in US men (CDC, 2012-2016)?

Applies to: HPV-attributable cancer in the United States (CDC data cited by the manufacturer)

> “Certain HPV-related oropharyngeal cancers—Certain oropharyngeal cancers were the most common HPV-related cancers in men and affect men more than women.<sup>b,6,7</sup> Not all oropharyngeal cancers are HPV-related.<sup>6</sup>”

Source: [GARDASIL 9: Recommending GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-pd/#:~:text=Certain%20HPV%2Drelated%20oropharyngeal%20cancers%E2%80%94Certain%20oropharyngeal,Not%20all%20oropharyngeal%20cancers%20are)

> “<sup>b</sup>Per 2012-2016 CDC data.”

Source: [GARDASIL 9: Recommending GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-pd/#:~:text=2012%2D2016%20CDC%20data.)

> “The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.”

Source: [GARDASIL 9: Recommending GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-pd/#:~:text=The%20oropharyngeal%20and%20head%20and,benefit%20in%20a%20confirmatory%20trial.)

## Related pages
- [Medical information: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): Human papillomavirus vaccination](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination)
- [Clinical trials](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/safety)
- [Specific populations](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/guidelines)
